018680 — Seoul Pharma Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMicro CapNeutral

Annual income statement for Seoul Pharma Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	R2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	53,950	52,232	40,463	50,057	52,459
Cost of Revenue
Gross Profit	30,604	35,228	25,483	32,146	31,588
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	50,442	41,919	46,375	50,495	51,246
Operating Profit	3,508	10,313	-5,912	-438	1,213
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	388	-1,174	-9,592	-1,120	4,044
Provision for Income Taxes
Net Income After Taxes	-1,869	-1,342	-9,689	855	3,517
Net Income Before Extraordinary Items
Net Income	-1,869	-1,342	-9,689	855	3,517
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-1,869	-1,342	-9,689	855	3,517
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-209	-479	-1,122	253	302
Dividends per Share